Clinical risk prediction model for 30-day all-cause re-hospitalisation or mortality in patients hospitalised with heart failure. (1st March 2022)

• Record Type: Journal Article
• Authors: Driscoll, A.; Romaniuk, H.; Dinh, D.; Amerena, J.; Brennan, A.; Hare, D.L.; Kaye, D.; Lefkovits, J.; Lockwood, S.; Neil, C.; Prior, D.; Reid, C.M.; Orellana, L.
• Is Part Of: International journal of cardiology. Volume 350(2022)
• Page Start: 69
• Page End: 76
• Publication Date: 2022-03-01
• Subjects: Heart failure -- Risk prediction model -- Re-hospitalisation -- Mortality; Cardiology -- Periodicals; Electronic journals; 616.12
• DOI: 10.1016/j.ijcard.2021.12.051
• Languages: English
• ISSNs: 0167-5273

Abstract

Abstract: Background: This study aimed to develop a risk prediction model (AUS-HF model) for 30-day all-cause re-hospitalisation or death among patients admitted with acute heart failure (HF) to inform follow-up after hospitalisation. The model uses routinely collected measures at point of care. Methods: We analyzed pooled individual-level data from two cohort studies on acute HF patients followed for 30-days after discharge in 17 hospitals in Victoria, Australia (2014–2017). A set of 58 candidate predictors, commonly recorded in electronic medical records (EMR) including demographic, medical and social measures were considered. We used backward stepwise selection and LASSO for model development, bootstrap for internal validation, C-statistic for discrimination, and calibration slopes and plots for model calibration. Results: The analysis included 1380 patients, 42.1% female, median age 78.7 years (interquartile range = 16.2), 60.0% experienced previous hospitalisation for HF and 333 (24.1%) were re-hospitalised or died within 30 days post-discharge. The final risk model included 10 variables (admission: eGFR, and prescription of anticoagulants and thiazide diuretics; discharge: length of stay>3 days, systolic BP, heart rate, sodium level (<135 mmol/L), >10 prescribed medications, prescription of angiotensin converting enzyme inhibitors or angiotensin receptor blockers, and anticoagulants prescription. The discrimination of the model was moderate (C-statistic = 0.684, 95%CI 0.653, 0.716; optimism estimate = 0.062) with good calibration. Conclusions: The AUS-HF model incorporating routinely collected point-of-care data from EMRs enables real-time risk estimation and can be easily implemented by clinicians. It can predict with moderate accuracy risk of 30-day hospitalisation or mortality and inform decisions around the intensity of follow-up after hospital discharge. Highlights: The AUS-HF model enables real-time-risk estimation at the bedside. AUS-HF comprises of routine point-of-care data from electronic medical records. Model discrimination was moderate with a c-statistic of 0.684 and good calibration. AUS-HF is a clinical decision tool to inform the intensity of post-discharge support.